Home » Stocks » GOSS

Gossamer Bio, Inc. (GOSS)

Stock Price: $10.29 USD -0.21 (-2.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $10.62 +0.33 (3.21%) Jan 15, 7:22 PM
Market Cap 781.30M
Revenue (ttm) n/a
Net Income (ttm) -233.45M
Shares Out 72.25M
EPS (ttm) -3.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $10.29
Previous Close $10.50
Change ($) -0.21
Change (%) -2.00%
Day's Open 10.36
Day's Range 10.22 - 10.60
Day's Volume 328,324
52-Week Range 8.00 - 15.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeuti...

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

Seeking Alpha - 2 months ago

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeuti...

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeuti...

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeuti...

CNBC Television - 2 months ago

These are the stocks seeing the most insider buying this week

In his weekly exclusive for Worldwide Exchange, Brian Sullivan highlights three stocks seeing the most insider buying this week, including some biotech names.

Other stocks mentioned: MDT, SELB
Seeking Alpha - 3 months ago

Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: CERS
GuruFocus - 3 months ago

Investors reacted forcefully Tuesday after Gossamer Bio Inc.'s (NASDAQ:GOSS) drug designated GB001 failed to achieve the hoped-for outcome in a study of patients with asthma and chronic sinus ...

24/7 Wall Street - 3 months ago

Gossamer Bio Inc. (NASDAQ: GOSS) shares dived on Tuesday after the company announced midstage results from its asthma and chronic rhinosinusitis studies.

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), today announced multiple updates for its GB004 program. GB004 is an oral, gut-targeted HIF-1α stabilizer, designed to promote muc...

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeuti...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeuti...

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeuti...

Zacks Investment Research - 5 months ago

As of late, it has definitely been a great time to be an investor in Gossamer Bio.

Benzinga - 7 months ago

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino.

Other stocks mentioned: GLNG, GWPH, LX, NXTC, SINA, TIGO
PRNewsWire - 7 months ago

NEW YORK, May 20, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company")(NASDAQ:GOSS) of the J...

The Motley Fool - 7 months ago

Stock dilution is on the way for the small biotech.

Seeking Alpha - 8 months ago

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: ACRX, AVGR, GNCA, VFF
Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor Gossamer Bio

Zacks Investment Research - 9 months ago

Gossamer Bio (GOSS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Benzinga - 1 year ago

Gossamer Bio Inc (NASDAQ: GOSS) shares are tumbling to their lowest level since Oct.

Investors Business Daily - 1 year ago

Shares of biotech company Gossamer Bio tumbled in high volume Monday after rival pharmaceutical company Novartis scrapped an asthma treatment that failed to meet its goal in a Phase 3 study. ...

The Motley Fool - 1 year ago

Novartis is throwing in the towel on a drug similar to Gossamer's lead candidate.

Seeking Alpha - 1 year ago

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

Fresh off an initial public offering, the pharmaceutical company has taken investors on a wild ride.

About GOSS

Gossamer Bio, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial i... [Read more...]

Industry
Biotechnology
IPO Date
Feb 8, 2019
CEO
Sheila Gujrathi
Employees
171
Stock Exchange
NASDAQ
Ticker Symbol
GOSS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Gossamer Bio stock is "Buy." The 12-month stock price forecast is 20.86, which is an increase of 102.72% from the latest price.

Price Target
$20.86
(102.72% upside)
Analyst Consensus: Buy